Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis
Abstract Background The effect and safety of atropine on delaying the progression of myopia has been extensively studied, but its optimal dose is still unclear. Therefore, the purpose of this meta-analysis is to systematically evaluate the safety and effectiveness of atropine in controlling the prog...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-12-01
|
| Series: | BMC Ophthalmology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12886-020-01746-w |
| _version_ | 1818844658412814336 |
|---|---|
| author | Congling Zhao Chunyan Cai Qiang Ding Hongbin Dai |
| author_facet | Congling Zhao Chunyan Cai Qiang Ding Hongbin Dai |
| author_sort | Congling Zhao |
| collection | DOAJ |
| description | Abstract Background The effect and safety of atropine on delaying the progression of myopia has been extensively studied, but its optimal dose is still unclear. Therefore, the purpose of this meta-analysis is to systematically evaluate the safety and effectiveness of atropine in controlling the progression of myopia, and to explore the relationship between the dose of atropine and the effectiveness of controlling the progression of myopia. Methods This work was done through the data searched from PubMed, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. The Cochrane Handbook was also used to evaluate the quality of the included studies. In addition, a meta-analysis was performed using Revman5.3 software. Results A total of 10 randomized controlled trials (RCTs) were included. Myopia progression was mitigated greater in the atropine treatment group than that in the control group, with MD = − 0.80, 95% CI (− 0.94, − 0.66) during the whole observation period. There was a statistical difference among 0.05, 0.5, and 1.0% atropine (P = 0.004). In addition, less axial elongation was shown, with MD = − 0.26, 95% CI (− 0.33, − 0.18) during the whole observation period. Conclusion The effectiveness of atropine in controlling the progression of myopia was dose related. A 0.05% atropine was likely to be the optimal dose. |
| first_indexed | 2024-12-19T05:17:16Z |
| format | Article |
| id | doaj.art-9c213cb58ab0481f9eaa644a2c3ed6b1 |
| institution | Directory Open Access Journal |
| issn | 1471-2415 |
| language | English |
| last_indexed | 2024-12-19T05:17:16Z |
| publishDate | 2020-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Ophthalmology |
| spelling | doaj.art-9c213cb58ab0481f9eaa644a2c3ed6b12022-12-21T20:34:38ZengBMCBMC Ophthalmology1471-24152020-12-012011810.1186/s12886-020-01746-wEfficacy and safety of atropine to control myopia progression: a systematic review and meta-analysisCongling Zhao0Chunyan Cai1Qiang Ding2Hongbin Dai3Aier Eye Hospital of Wuhan universityAier Eye Hospital of Wuhan universityDepartment of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAier Eye Hospital of Wuhan universityAbstract Background The effect and safety of atropine on delaying the progression of myopia has been extensively studied, but its optimal dose is still unclear. Therefore, the purpose of this meta-analysis is to systematically evaluate the safety and effectiveness of atropine in controlling the progression of myopia, and to explore the relationship between the dose of atropine and the effectiveness of controlling the progression of myopia. Methods This work was done through the data searched from PubMed, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. The Cochrane Handbook was also used to evaluate the quality of the included studies. In addition, a meta-analysis was performed using Revman5.3 software. Results A total of 10 randomized controlled trials (RCTs) were included. Myopia progression was mitigated greater in the atropine treatment group than that in the control group, with MD = − 0.80, 95% CI (− 0.94, − 0.66) during the whole observation period. There was a statistical difference among 0.05, 0.5, and 1.0% atropine (P = 0.004). In addition, less axial elongation was shown, with MD = − 0.26, 95% CI (− 0.33, − 0.18) during the whole observation period. Conclusion The effectiveness of atropine in controlling the progression of myopia was dose related. A 0.05% atropine was likely to be the optimal dose.https://doi.org/10.1186/s12886-020-01746-wAtropineMyopia progressionMeta-analysis |
| spellingShingle | Congling Zhao Chunyan Cai Qiang Ding Hongbin Dai Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis BMC Ophthalmology Atropine Myopia progression Meta-analysis |
| title | Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis |
| title_full | Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis |
| title_fullStr | Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis |
| title_short | Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis |
| title_sort | efficacy and safety of atropine to control myopia progression a systematic review and meta analysis |
| topic | Atropine Myopia progression Meta-analysis |
| url | https://doi.org/10.1186/s12886-020-01746-w |
| work_keys_str_mv | AT conglingzhao efficacyandsafetyofatropinetocontrolmyopiaprogressionasystematicreviewandmetaanalysis AT chunyancai efficacyandsafetyofatropinetocontrolmyopiaprogressionasystematicreviewandmetaanalysis AT qiangding efficacyandsafetyofatropinetocontrolmyopiaprogressionasystematicreviewandmetaanalysis AT hongbindai efficacyandsafetyofatropinetocontrolmyopiaprogressionasystematicreviewandmetaanalysis |